NeoStem : Caladrius Biosciences to Participate at Upcoming June Conferences
June 01, 2017 at 08:01 am EDT
Share
BASKING RIDGE, N.J. (June 1, 2017) - Caladrius Biosciences, Inc. (NASDAQ:CLBS) ('Caladrius' or the 'Company'), a clinical stage development company with a cell therapy pipeline focused on immune modulation and select cardiovascular indications, announces today that the Company's leadership will participate at the following upcoming June conferences:
7 Annual LD Micro Invitational
14 International Symposium on Stem Cell Therapy & Cardiovascular Innovations
Session 1
Date and Time: Thursday, June 15, 2017, 12:00 PM CET
Panel: What's New in Cardiovascular Regenerative Medicine?
Panelist: Douglas W. Losordo, MD, Chief Medical Officer, Caladrius
Session 2
Date and Time: Thursday, June 15, 2017, 4:20 PM CET
Panel: The 2017 Debate
Panelist: Douglas W. Losordo, MD, Chief Medical Officer, Caladrius
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical stage development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and select cardiology indications. The Company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes in a currently enrolling Phase 2 trial. For more information on Caladrius please visit www.caladrius.com.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the 'Risk Factors' described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ('SEC') on March 17, 2017, and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.
Caladrius Biosciences Inc. published this content on 01 June 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 01 June 2017 12:01:19 UTC.
Original documenthttp://www.caladrius.com/press-release/caladrius-biosciences-to-participate-at-upcoming-june-conferences/
Public permalinkhttp://www.publicnow.com/view/A6BDD4FC774C73F41CDF86083590BC1541BC20B5
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.